medigraphic.com
Colegio de Medicina Interna de México.

2023, Número 1

<< Anterior Siguiente >>

Med Int Mex 2023; 39 (1)


Tocilizumab, recurso terapéutico de vanguardia contra la infección por SARS-CoV-2: una revisión exploratoria

Tuta-Quintero E, Mora-Karam C, Camacho-Osorio J, Rhenals-Acuña S, Arrieta-Acuña F, Pérez-Mantilla D, Cristiano-Alvarado N, Pimentel J

Idioma: Español
Referencias bibliográficas: 63
Paginas: 66-90
Archivo PDF: 311.98 Kb.


RESUMEN

Objetivo: Explorar la evidencia médica publicada hasta el 20 de abril de 2022 acerca de la eficacia y la seguridad del tocilizumab en pacientes con COVID-19.
Metodología: Revisión exploratoria que incluyó bases de datos como PubMed y Scopus, buscando ensayos clínicos y estudios observacionales analíticos en inglés y español. Asimismo, se analizaron registros de ensayos clínicos de la Plataforma de Registros Internacionales de Ensayos Clínicos de la Organización Mundial de la Salud.
Resultados: Cincuenta y cuatro documentos se incluyeron en la evaluación final: estudios de cohorte retrospectiva (n = 20), ensayos clínicos con distribución al azar (n = 16), casos y controles (n = 7), ensayos clínicos sin distribución al azar (n = 5) y estudios de cohorte prospectiva (n = 6), sumando una población total de 20,007 pacientes. Además, se encontraron 15 registros de ensayos clínicos, de los cuales 10 estaban registrados en US National Library of Medicine.
Conclusiones: El tocilizumab podría ser eficaz y seguro en el contexto de pacientes con diagnóstico de COVID-19 moderado a crítico, en conjunto con otros inmunomoduladores y antivirales. Sin embargo, se requiere un mayor número de ensayos clínicos con distribución al azar y evaluación estricta de los efectos adversos asociados con el bloqueo del receptor de IL-6, en conjunto con otros fármacos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Wu JT, Leung K, Leung GM. Nowcasting and forecastingthe potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modellingstudy. Lancet 2020; 395: 689-697. doi: 10.1016/S0140-6736(20)30260-9.

  2. Salzberger B, Buder F, Lampl B, Ehrenstein B, HitzenbichlerF, Hanses F. Epidemiologie von SARS-CoV-2-Infektion undCOVID-19 [Epidemiology of SARS-CoV-2 infection andCOVID-19]. Internist (Berl) 2020; 61 (8): 782-788. doi:10.1007/s00108-020-00834-9.

  3. Wu Z, McGoogan JM. Characteristics of and importantlessons from the coronavirus disease 2019 (COVID-19)outbreak in China: Summary of a report of 72,314 casesfrom the Chinese Center for Disease Control and Prevention.JAMA 2020; 323 (13): 1239-1242. doi: 10.1001/jama.2020.2648.

  4. Tuta-Quintero E, Vega-Corredor MC, Perdomo-RodríguezLS, Pimentel J. Colchicina, perspectivas de un viejo amigopara la reumatología en la COVID-19: una revisiónexploratoria. Rev Colomb Reumatol 2020. https://doi.org/10.1016/j.rcreu.2021.02.002.

  5. Fu B, Xu X, Wei H. Why tocilizumab could be an effectivetreatment for severe COVID-19? J Transl Med 2020; 18 (1):164. doi: 10.1186/s12967-020-02339-3.

  6. Alzghari SK, Acuña VS. Supportive treatment with tocilizumabfor COVID-19: a systematic review. J Clin Virol 2020;127: 104380. doi: 10.1016/j.jcv.2020.104380.

  7. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R.The COVID-19 cytokine storm; what we know so far. FrontImmunol 2020; 11: 1446. doi: 10.3389/fimmu.2020.01446.

  8. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, LevacD, et al. PRISMA Extension for Scoping Reviews (PRISMAScR):Checklist and explanation. Ann Intern Med 2018; 169:467. https://doi.org/10.7326/M18-0850.

  9. Arksey H, O’Malley L. Scoping studies: towards a methodologicalframework. Int J Soc Res Methodol 2005; 8: 19-32.doi:10.1080/1364557032000119616.

  10. Levac D, Colquhoun H, O’Brien KK. Scoping studies:advancing the methodology. Implement Sci 2010; 5: 69.doi:10.1186/1748-5908-5-69.

  11. World Health Organization (WHO). WHO registry network[Internet]. 2020 [consultado: 7 Mayo 2021]. Disponible en:https://www.who.int/ictrp/network/primary/en/.

  12. Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M,Boffini N, et al. Efficacy and safety of tocilizumab in severeCOVID-19 patients: a single-centre retrospective cohortstudy. Eur J Intern Med 2020; 76: 43-49. doi: 10.1016/j.ejim.2020.05.021.

  13. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, MelamedML, et al. Association between early treatment withtocilizumab and mortality among critically ill patients withCOVID-19. JAMA Intern Med 2021; 181 (1): 41-51. doi:10.1001/jamainternmed.2020.6252.

  14. Menzella F, Fontana M, Salvarani C, Massari M, RuggieroP, Scelfo C, et al . Efficacy of tocilizumab in patients withCOVID-19 ARDS undergoing noninvasive ventilation.Crit Care 2020; 24 (1): 589. doi: 10.1186/s13054-020-03306-6.

  15. Rossotti R, Travi G, Ughi N, Corradin M, Baiguera C, FumagalliR, et al. Safety and efficacy of anti-il6-receptortocilizumab use in severe and critical patients affected bycoronavirus disease 2019: A comparative analysis. J Infect2020; 81 (4): e11-e17. doi: 10.1016/j.jinf.2020.07.008.

  16. Roumier M, Paule R, Vallée A, Rohmer J, Ballester M, BrunAL, et al. Tocilizumab for severe worsening COVID-19pneumonia: A propensity score analysis. J Clin Immunol2021; 41 (2): 303-314. doi: 10.1007/s10875-020-00911-6.

  17. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, HarveyL, Foulkes AS, et al. Efficacy of tocilizumab in patientshospitalized with Covid-19. N Engl J Med 2020; 383 (24):2333-2344. doi: 10.1056/NEJMoa2028836.

  18. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, etal. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.N Engl J Med 2021; 384 (1): 20-30. doi: 10.1056/NEJMoa2030340.

  19. Zhao H, Zhu Q, Zhang C, Li J, Wei M, Qin Y, et al. Tocilizumabcombined with favipiravir in the treatment ofCOVID-19: A multicenter trial in a small sample size. BiomedPharmacother. 2021; 133: 110825. doi: 10.1016/j.biopha.2020.110825.

  20. Horby P, Pessoa-Amorim G, Peto L, Brightling C, SarkarR, Thomas K, et al. tocilizumab in patients admitted tohospital with COVID-19 (RECOVERY): a randomised, controlled,open-label, platform trial. Lancet 2021. https://doi.org/10.1016/S0140-6736(21)00676-0.

  21. Rosas IO, Diaz G, Gottlieb RL, Lobo SM, Robinson P, HunterBD, et al. Tocilizumab and remdesivir in hospitalizedpatients with severe COVID-19 pneumonia: a randomizedclinical trial. Intensive Care Med 2021; 47 (11): 1258-1270.doi: 10.1007/s00134-021-06507-x.

  22. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M,Porcher R, Ravaud P, et al. Effect of tocilizumab vs usualcare in adults hospitalized with COVID-19 and moderateor severe pneumonia: A randomized clinical trial. JAMAIntern Med 2021; 181 (1): 32-40. doi: 10.1001/jamainternmed.2020.6820.

  23. Rosas I, Bräu N, Waters M, Go R, Hunter B, Bhagani S,et al. Tocilizumab in hospitalized patients with severeCovid-19 pneumonia. N Engl J Med 2021. doi:10.1056/NEJMoa2028700.

  24. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, SavoldiL, et al. Effect of tocilizumab vs standard care on clinicalworsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial. JAMA Intern Med 2021;181 (1): 24-31. doi: 10.1001/jamainternmed.2020.6615.

  25. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, etal. Tocilizumab in patients hospitalized with Covid-19 pneumonia.N Engl J Med 2021; 384 (1): 20-30. doi: 10.1056/NEJMoa2030340.

  26. Veiga VC, Prats JAGG, Farias DLC, Rosa RG, Dourado LK,Zampieri FG, et al. Effect of tocilizumab on clinical outcomesat 15 days in patients with severe or critical coronavirusdisease 2019: randomised controlled trial. BMJ 2021;372: n84. doi: 10.1136/bmj.n84.

  27. Gordon A, Mouncey P, Al-Beidh F, Rowan KM, Nichol AD,Arabi YM, et al. Interleukin-6 receptor antagonists incritically ill patients with Covid-19. N. Engl. J. Med 2021.https://doi.org/10.1101/2021.01.07.21249390.

  28. Lin WT, Hung SH, Lai CC, Wang CY, Chen CH. The effect oftocilizumab on COVID-19 patient mortality: A systematicreview and meta-analysis of randomized controlled trials.Int Immunopharmacol 2021; 96: 107602. doi:10.1016/j.intimp.2021.107602.

  29. Kow CS, Hasan SS. The effect of tocilizumab on mortalityin hospitalized patients with COVID-19: a meta-analysis ofrandomized controlled trials. Eur J Clin Pharmacol 2021:1-6. doi: 10.1007/s00228-021-03087-z.

  30. Kaminski MA, Sunny S, Balabayova K, Kaur A, Gupta A,Abdallah M, et al. Tocilizumab therapy for COVID-19:A comparison of subcutaneous and intravenous therapies.Int J Infect Dis 2020; 101: 59-64. doi: 10.1016/j.ijid.2020.09.1447.

  31. Van den Eynde E, Gasch O, Oliva JC, Prieto E, Calzado S,Gomila A, et al. Corticosteroids and tocilizumab reduce inhospitalmortality in severe COVID-19 pneumonia: a retrospectivestudy in a Spanish hospital. Infect Dis (Lond) 2021;53 (4): 291-302. doi: 10.1080/23744235.2021.1884286.

  32. Tian J, Zhang M, Jin M, Zhang F, Chu Q, Wang X, et al.Repurposed tocilizumab in patients with severe COVID-19.J Immunol 2021; 206 (3): 599-606. doi: 10.4049/jimmunol.2000981.

  33. Martínez-Sanz J, Muriel A, Ron R, Herrera S, Pérez-MolinaJA, Moreno S, et al. Effects of tocilizumab on mortality inhospitalized patients with COVID-19: a multicentre cohortstudy. Clin Microbiol Infect 2021; 27 (2): 238-243. doi:10.1016/j.cmi.2020.09.021.

  34. Pérez-Sáez MJ, Blasco M, Redondo-Pachón D, Ventura-Aguiar P, Bada-Bosch T, Pérez-Flores I, et al. Use of tocilizumabin kidney transplant recipients with COVID-19.Am J Transplant 2020; 20 (11): 3182-3190. doi: 10.1111/ajt.16192.

  35. Maritati F, Cerutti E, Zuccatosta L, Fiorentini A, Finale C, FicoseccoM, et al; SARS-CoV-2 infection in kidney transplantrecipients: Experience of the Italian marche region. TransplInfect Dis 2020; 22 (5): e13377. doi: 10.1111/tid.13377.

  36. Hammami MB, Garibaldi B, Shah P, Liu G, Jain T, Chen PH, etal. Clinical course of COVID-19 in a liver transplant recipienton hemodialysis and response to tocilizumab therapy: Acase report. Am J Transplant 2020; 20 (8): 2254-2259. doi:10.1111/ajt.15985.

  37. Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z, et al. Firstcase of COVID-19 in a patient with multiple myelomasuccessfully treated with tocilizumab. Blood Adv 2020; 4(7): 1307-1310. doi: 10.1182/bloodadvances.2020001907.

  38. Michot JM, Albiges L, Chaput N, Saada V, Pommeret F,Griscelli F, et al. Tocilizumab, an anti-IL-6 receptor antibody,to treat COVID-19-related respiratory failure: a casereport. Ann Oncol 2020; 31 (7): 961-964. doi: 10.1016/j.annonc.2020.03.300.

  39. Mihai C, Dobrota R, Schröder M, Garaiman A, Jordan S,Becker MO, Maurer B, et al. COVID-19 in a patient withsystemic sclerosis treated with tocilizumab for SSc-ILD.Ann Rheum Dis 2020; 79 (5): 668-669. doi: 10.1136/annrheumdis-2020-217442.

  40. Valencia-Sanchez C, Wingerchuk DM. A fine balance: Immunosuppressionand immunotherapy in a patient withmultiple sclerosis and COVID-19. Mult Scler Relat Disord.2020; 42: 102182. doi: 10.1016/j.msard.2020.102182.

  41. Coskun Benlidayi I, Kurtaran B, Tirasci E, Guzel R. Coronavirusdisease 2019 (COVID-19) in a patient with ankylosingspondylitis treated with secukinumab: a case-based review.Rheumatol Int 2020; 40 (10): 1707-1716. doi: 10.1007/s00296-020-04635-z.

  42. Swiss Federal Office of Public Health. New coronavirus: documentsfor health professionals. [Accedido el 30 de abrilde 2021] Available: https://www.bag.admin.ch/bag/de/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-ausbrueche-epidemien/novel-cov/informationfuer-die-aerzteschaft/dokumente-fuer-gesundheitsfachpersonen.html.

  43. Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS,Chakraborty C. Tocilizumab: A therapeutic option forthe treatment of cytokine storm syndrome in COVID-19.Arch Med Res 2020; 51 (6): 595-597. doi: 10.1016/j.arcmed.2020.05.009.

  44. Kang S, Tanaka T, Narazaki M, Kishimoto T. Targetinginterleukin-6 signaling in clinic. Immunity 2019; 50 (4):1007-1023. doi: 10.1016/j.immuni.2019.03.026.

  45. Patel K, Gooley TA, Bailey N, Bailey M, Hegerova L, BatchelderA, et al. Use of the IL-6R antagonist tocilizumab inhospitalized COVID-19 patients. J Intern Med 2021; 289(3): 430-433. doi: 10.1111/joim.13163.

  46. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatmentin COVID-19: A single center experience. J Med Virol 2020;92 (7): 814-818. doi: 10.1002/jmv.25801.

  47. Rezaee H, Pourkarim F, Pourtaghi-Anvarian S, Entezari-Maleki T, Asvadi-Kermani T, Nouri-Vaskeh M. Drug-druginteractions with candidate medications used for COVID-19treatment: An overview. Pharmacol Res Perspect 2021; 9(1): e00705. doi: 10.1002/prp2.705.

  48. Hoeltzenbein M, Beck E, Rajwanshi R, Gøtestam Skorpen C,Berber E, Schaefer C, et al. Tocilizumab use in pregnancy:Analysis of a global safety database including data fromclinical trials and post-marketing data. Semin ArthritisRheum 2016; 46 (2): 238-245. doi: 10.1016/j.semarthrit.2016.05.004.

  49. Rivera-Izquierdo M, Valero-Ubierna MDC, R-del Amo JL,Fernández-García MÁ, Martínez-Diz S, Tahery-Mahmoud A,et al. Therapeutic agents tested in 238 COVID-19 hospitalizedpatients and their relationship with mortality. Med Clin (Barc)2020; 155 (9): 375-381. doi: 10.1016/j.medcli.2020.06.025.

  50. Sanz-Herrero F, Puchades-Gimeno F, Ortega-García P,Ferrer-Gómez C, Ocete-Mochón MD, García-Deltoro M.Methylprednisolone added to tocilizumab reduces mortalityin SARS-CoV-2 pneumonia: An observational study. J InternMed 2021; 289 (2): 259-263. doi: 10.1111/joim.13145.

  51. Callejas-Rubio JL, Luna-Del Castillo JD, De la Hera-FernándezJ, Guirao-Arrabal E, Colmenero-Ruiz M, Ortego-Centeno N. Effectiveness of corticoid pulses in patientswith cytokine storm syndrome induced by SARS-CoV-2infection. Med Clin (Barc) 2020; 155 (4): 159-161. doi:10.1016/j.medcli.2020.04.018.

  52. Emmi G, Bettiol A, Mattioli I, Silvestri E, Scala G Di, UrbanML, et al. SARS-CoV-2 infection among patients with systemicautoimmune diseases. Autoimmun Rev 2020; 19 (7):102575. https://doi.org/10.1016/j.autrev.2020.102575.

  53. Naqvi M, Zakowski P, Glucksman L, Smithson S, Burwick RM.Tocilizumab and remdesivir in a pregnant patient with coronavirusdisease 2019 (COVID-19). Obstet Gynecol 2020; 136(5): 1025-1029. doi: 10.1097/AOG.0000000000004050.

  54. Innes AJ, Cook LB, Marks S, Bataillard E, Crossette-ThambiahC, Sivasubramaniam G, et al. Ruxolitinib for tocilizumabrefractorysevere COVID-19 infection. Br J Haematol 2020;190 (4): e198-200. https://doi.org/10.1111/bjh.16979.

  55. Portsmore S, Tran Nguyen TN, Beacham E, NeelakantanP. Combined IL-6 and JAK/STAT inhibition therapy inCOVID-19-related sHLH, potential game changer. Br JHaematol 2020; 190 (4): 525-8. Available from: https://doi.org/10.1111/bjh.16966.

  56. Zhao H, Zhu Q, Zhang C, Li J, Wei M, Qin Y, et al. Tocilizumabcombined with favipiravir in the treatment ofCOVID-19: A multicenter trial in a small sample size.Biomed Pharmacother 2021; 133: 110825. doi: 10.1016/j.biopha.2020.110825.

  57. Langer-Gould A, Smith JB, Gonzales EG, Castillo RD,Figueroa JG, Ramanathan A, et al. Early identification ofCOVID-19 cytokine storm and treatment with anakinraor tocilizumab. Int J Infect Dis 2020; 99: 291-297. doi:10.1016/j.ijid.2020.07.081.

  58. Pettit NN, Nguyen CT, Mutlu GM, Wu D, Kimmig L, PitrakD, et al. Late onset infectious complications and safety oftocilizumab in the management of COVID-19. J Med Virol2021; 93 (3): 1459-1464. doi: 10.1002/jmv.26429.

  59. Sheppard M, Laskou F, Stapleton PP, Hadavi S, DasguptaB. Tocilizumab (Actemra). Hum Vaccin Immunother 2017;13 (9): 1972-1988. doi: 10.1080/21645515.2017.1316909.

  60. Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K,Demary W. Risk for lower intestinal perforations in patientswith rheumatoid arthritis treated with tocilizumab in comparisonto treatment with other biologic or conventionalsynthetic DMARDs. Ann Rheum Dis 2017; 76: 504-510. doi:10.1136/annrheumdis-2016-209773.

  61. Vikse J, Henry BM. Tocilizumab in COVID-19: Beware therisk of intestinal perforation. Int J Antimicrob Agents 2020;56 (1): 106009. doi: 10.1016/j.ijantimicag.2020.106009.

  62. Montorfano L, Miret R, Rahman AU, Alonso M, Maron DJ,Roy M, et al. Colorectal surgery obesity-related morbidityduring COVID-19. Surg Obes Relat Dis 2020; 16 (9): 1372-5.doi: 10.1016/j.soard.2020.06.011.

  63. Antinori S, Bonazzetti C, Gubertini G, Capetti A, PaganiC, Morena V, Rimoldi S, Galimberti L, Sarzi-Puttini P,Ridolfo AL. Tocilizumab for cytokine storm syndrome inCOVID-19 pneumonia: an increased risk for candidemia?Autoimmun Rev 2020; 19 (7): 102564. doi: 10.1016/j.autrev.2020.102564.




2020     |     www.medigraphic.com